Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
05/2005
05/19/2005WO2005025520A3 Chitosan spinning method, device therefor, and resulting chitosan yarn, and uses thereof
05/19/2005WO2005014576A8 Isoquinolinone derivative, process for producing the same and use thereof
05/19/2005WO2004087063A3 Use of erythropoietin in stroke recovery
05/19/2005WO2004016764A3 eNOS MUTANTS USEFUL FOR GENE THERAPY
05/19/2005WO2004015125A9 Process for preparing peptides with anti-hypertensive properties
05/19/2005WO2003014703A3 Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof
05/19/2005WO2003009815A3 Compositions and methods for modulating blood-brain barrier transport
05/19/2005US20050108785 Using nuclear transplantation as tool in generating transgenic cells for treatment and prevention of liver, nervous system, cardiovascular and bone disorders; regenerative medicine
05/19/2005US20050107611 For use as adenosine receptor ligands; immunostimulants; contraceptives
05/19/2005US20050107472 administering vitamin k derivatives for prophylaxis of neurodegenerative diseases associated with protein aggregation or neurofibrillary tangles
05/19/2005US20050107458 used as diagnostic kits, bioassay and/or drugs for preventing cancers, Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, stroke, ischaemia, Huntington's disease, epilepsy, multiple sclerosis, neuropathy, or injuries of the brain or spinal chord, or as tyrosine kinase inhibitors
05/19/2005US20050107457 Indazole derivatives as JNK inhibitors and compositions and methods related thereto
05/19/2005US20050107450 administering Peroxisome Proliferator Activated Receptors (PPAR-gamma) activators according to a dosage schedule which comprises a cycle of less than daily administration
05/19/2005US20050107449 Substituted thiazoles and oxazoles, e.g., 4-{1-[4-[2-(2-Chloro-6-fluoro-phenyl)-ethyl]-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid; treating atherosclerosis and diabetes and creating Syndrome X
05/19/2005US20050107446 Two components mixture comprising a powder of atorvastatin with an alkalizing agent that forms a pH greater than 5 and a second component without the alkalizing agent; treating angina pectoris, hypertension, atherosclerosis
05/19/2005US20050107442 Compounds that modulate PPAR activity and methods of preparation
05/19/2005US20050107441 screening for drugs that alter glucose production by modulating gene expression and/or activity of the nuclear receptor short heterodimer partners, then using the drugs as hypoglycemic or hyperglycemic agents; antidiabetic agents; metabolic disorders
05/19/2005US20050107428 Antiinflammatory agents; autoimmune diseases; rheumatic diseases; anticholesterol agents; cardiovascular disorders
05/19/2005US20050107416 17-hydroxy 4-aza androstan -3-ones as androgen receptor modulators
05/19/2005US20050107413 pyrimidine derivatives such as 4-Chloro-5,6-diphenyl-2-(trifluoromethyl)pyrimidine, used for the treatment of inflammation and immunological diseases
05/19/2005US20050107410 Compound possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders
05/19/2005US20050107406 Angiogenesis inhibitors
05/19/2005US20050107394 Novel use of selective pde5 inhibitors
05/19/2005US20050107392 treatment of disease such as diabetes, obesity, hyperlipidemia, and atherosclerotic disease; e.g. ethyl (5-methoxy-2,3-dihydro-1H-inden-1-ylidene)ethanoate
05/19/2005US20050107390 i.e. 7-[(3R)-3-Amino-4-(3,4-difluorophenyl)butanoyl]-3-methyl-6-(phenylmethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazine, dihydrochloride; antilipemic, antiobesity
05/19/2005US20050107384 to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a HDAC in a biological sample comprising detecting or measuring the formation of a complex between a labelled compound as defined in claim (I) and a HDAC
05/19/2005US20050107379 antithrombolytic agents such as (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide, used for therapy of cardiovascular disorders
05/19/2005US20050107362 Indolamid derivatives which possess glycogenphosphorylase inhibitory activity
05/19/2005US20050107347 Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
05/19/2005US20050107345 Aminoalkylphosphonates and related compounds as edg receptor agonists
05/19/2005US20050107340 Protein kinase modulators; cancer, diabetes, hepatic cirrhosis, cardiovascular disease such as atherosclerosis, angiogenesis, immunological disease such as autoimmune disease (e.g., AIDS and lupus) and renal disease
05/19/2005US20050107331 Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect
05/19/2005US20050107323 Cardiac arrhythmia treatment methods
05/19/2005US20050107317 Nucleic acid molecule of the short-chain dehydrogenase gene family, an antibody, an aptamer or receptors, polypeptide encoded thereby; biodrug for treatment of metabolism of triglycerides, metabolic disorders as obesity, eating disorder, cachexia, diabetes mellitus, hypertension, heart disease
05/19/2005US20050107309 Lowering elevated post-prandial blood glucose levels by increasing incretin half-life comprising administering inhibitor of Dipeptidyl Peptidase (DP IV) or enzymes having DP-IV-like activity; insulinotropic effects are enhanced
05/19/2005US20050107294 in an injectable form and to be administered through infiltrations inside and around cutaneous chronic ischemic ulcerative wounds as to prevent diabetic limb amputation
05/19/2005US20050107293 Protein modification and maintenance polypeptides (PMOD) for use as diagnostic and therapeutic tools in treatment of prevention of gastrointestinal, cardiovascular, autoimmune/inflammatory, cell proliferative, developmental, epithelial, neurological, and reproductive disorders
05/19/2005US20050107291 Compositions and methods for treating or preventing diseases of body passageways
05/19/2005US20050106724 Self renewing dental follicle tissues for use in generating periodontal ligament like membrane structures; tissue repair and regenerative medicine
05/19/2005US20050106695 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
05/19/2005US20050106679 Leptin proteins
05/19/2005US20050106675 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
05/19/2005US20050106654 Animal model lacking histone deacetylase (HDAC) for use as diagnostic tool in detection, diagnosis and prevention of cardiac hypertrophy
05/19/2005US20050106638 Immunoglobulin for use in diagnosis, prevention and treatment of fibrosis and scarring; antiscarring agents
05/19/2005US20050106611 Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy
05/19/2005US20050106581 Phosphodiesterase polypeptides for use in identifying modulators for prevention and treatment of inflammatory disease
05/19/2005US20050106269 stimulating increased NO production; neuroprotectant; increased cerebral blood flow
05/19/2005US20050106266 docosahexaenoic acid and a calcium compound (carbonate, hydroxide,sulfate)
05/19/2005US20050106238 Orodispersible pharmaceutical composition comprising ivabradine
05/19/2005US20050106237 Orodispersible pharmaceutical composition comprising perindopril
05/19/2005US20050106212 Using electrochemical mixture of metal compound and bioactive material; contacting substrate
05/19/2005US20050106140 Antagonistic anti-hfas ligand human antibodies and fragments thereof
05/19/2005US20050106127 Graft to humans; culture product; removing cells; preservation
05/19/2005US20050106126 Compositions including ammonia oxidizing bacteria and methods of using same
05/19/2005US20050106099 Fusion proteins
05/19/2005DE10148828B4 Modulation der Expression STAT-1-abhängiger Gene Modulating the expression of STAT-1-dependent genes
05/19/2005CA2586320A1 Bonding tissues and cross-linking proteins with naphthalimide compounds
05/19/2005CA2549570A1 Medicament for prophylactic and/or therapeutic treamtent of cerebral infarction
05/19/2005CA2543481A1 G-csf therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
05/18/2005EP1531180A1 Method of diagnosing risk of myocardial infarction
05/18/2005EP1530632A2 Growth factor which acts through erb b-4 rtk
05/18/2005EP1530586A2 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
05/18/2005EP1530573A1 Condensed heterocyclic pyrazole derivatives as kinase inhibitors
05/18/2005EP1530568A1 INDOLE OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING I&kB KINASE
05/18/2005EP1530567A1 Pyridinyl substituted (1,2,3,)triazoles as inhibitors of the tgf-beta signalling pathway
05/18/2005EP1530566A1 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them
05/18/2005EP1530565A1 Substituted thiophene carboxamide compounds for the treatment of inflammation
05/18/2005EP1530564A2 Compounds derived from aryl carbamates, preparation thereof and uses of same
05/18/2005EP1530476A1 Use of reboxetine for the treatment of hot flashes
05/18/2005EP1530475A2 Pharmaceutical compositions comprising an allosteric carboxylic inhibitor of matrix metalloproteinase-13 and a selective inhibitor of cyclooxygenase-2
05/18/2005EP1530473A2 Regulation of erythrocyte apoptosis
05/18/2005EP1530463A1 L-arginine containing pharmaceutical composition
05/18/2005EP1436381B1 Dedifferentiated, programmable stem cells of monocytic origin, and their production and use
05/18/2005EP1389128A4 Method for inhibiting atherosclerotic plaque formation
05/18/2005EP1301502B1 Compounds and their use as glycine transport inhibitors
05/18/2005EP1265860B1 Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
05/18/2005EP1263724B1 Novel compounds
05/18/2005EP1259484B1 Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion
05/18/2005EP1224195B1 C-aryl glucoside sglt2 inhibitors
05/18/2005EP1098885B9 Imidazole compounds and their use as adenosine deaminase inhibitors
05/18/2005EP0839055B1 Modified methioninase, its use, recombinant host cells producing high levels of methioninase and method for purifying methioninase
05/18/2005EP0662137B1 Gene transcription and ionizing radiation: methods and compositions
05/18/2005CN1617884A Beta-amyloid binding factors and inhibitors thereof
05/18/2005CN1617883A Solid salts of benzazepine compounds and pharmaceutical compositions containing them
05/18/2005CN1617869A 4-(piperidyl- and pyrrolidyl-alkyl-ureido) -quinolines as urotensin ii receptor antagonists
05/18/2005CN1617859A 5-sulfanyl-4h-1, 2, 4-triazole derivatives and their use as a medicament
05/18/2005CN1617856A Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them
05/18/2005CN1617854A Pheny(alkyl)carboxylic acid derivatives and dionic phenylalkylheterocyclic derivatives and their use as medicines with serum glucose and/or serum lipid lowering activity
05/18/2005CN1617850A Dibenzylamine compound and medicinal use thereof
05/18/2005CN1617737A Compositions and method for normalizing lipid levels in mammalian tissues
05/18/2005CN1617732A Nuclear-envelope and nuclear-lamina binding chimeras for modulating gene expression
05/18/2005CN1617724A Neurotransmitter balance chemotherapy
05/18/2005CN1617722A Nicotin-or isonicotin benzothiazole derivatives
05/18/2005CN1617721A Substituted 2-thio-3, 5-dicyano-4-phenyl-6-aminopyridines and use thereof
05/18/2005CN1617718A N-aryl-N'-arylcycloalkyl-urea derivatives as MCH antagonists for the treatment of obesity
05/18/2005CN1617717A Pharmaceutical compositions of amlodipine and atorvastatin
05/18/2005CN1617711A Liposomal delivery of vitamin E based compounds
05/18/2005CN1616459A Adenosine derivatives
05/18/2005CN1616452A 维生素d类似物 Vitamin d analogues
05/18/2005CN1616381A Process for preparing Erigeron breviscapus active component
1 ... 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 ... 1595